[Lomefloxacin pharmacokinetics in patients in the terminal stage of chronic renal insufficiency, undergoing treatment with programmed hemodialysis].
The most frequent complications in patients with the terminal stage of chronic renal insufficiency are infections of various severity. The problem of the antibacterial therapy choice is especially urgent because of a high frequency of antibiotic resistant strains and the necessity to correct the treatment regimens in regard to the severity of the renal failure. The pharmacokinetics of lomefloxacin, a new fluoroquinolone, was studied in the treatment of patients with the terminal stage of chronic renal insufficiency treated by programmed hemodialysis. Lomefloxacin was administered orally in a dose of 400 mg at an interval of 48 hours 24 hours prior to the hemodialysis application. There was observed a decrease in the maximum serum concentration of the drug by comparison to that in healthy persons which could be due to slow absorption of the drug and hyperhydration in the patients because of anuria. In the treatment of such patients it is necessary to provide high serum concentrations of lomefloxacin attainable by using higher single doses of the drug.
Kolendo
S E
SE
Vorob'ev
P A
PA
Dvoretskiĭ
L I
LI
Izotova
G N
GN
Miagkov
A V
AV
Shvyreva
G S
GS
Iakovlev
S V
SV
D000890:Anti-Infective Agents / Q000493:pharmacokinetics*; D003131:Combined Modality Therapy; D024841:Fluoroquinolones; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy*; D015363:Quinolones / Q000493:pharmacokinetics*; D006435:Renal Dialysis
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C053091:lomefloxacin
Farmakokinetika lomefloksatsina u bol'nykh v terminal'noĭ pochechnoĭ nedostatochnosti, nakhodiashchikhsia na lechenii programmnym gemodializom.